轉(zhuǎn)化醫(yī)學國家重大科技基礎(chǔ)設(shè)施（上海）項目（簡稱大設(shè)施）于2013年7月經(jīng)國家發(fā)展和改革委員會正式批準立項，2016年9月啟動建設(shè),2020年12月正式運行。
作為國家級轉(zhuǎn)化醫(yī)學研究機構(gòu)，大設(shè)施由國家教育部和上海市共同管理，是我國首個綜合性國家級轉(zhuǎn)化醫(yī)學重大科技基礎(chǔ)設(shè)施。大設(shè)施以國家創(chuàng)新戰(zhàn)略和國家中長期科技發(fā)展規(guī)劃為導向，以促進前沿技術(shù)和基礎(chǔ)醫(yī)學研究成果向臨床應(yīng)用轉(zhuǎn)化為目標，結(jié)合上海交通大學和瑞金醫(yī)院的研究基礎(chǔ)和學科優(yōu)勢，選擇嚴重危害中國人群健康的腫瘤、代謝性疾病和心腦血管疾病等“三大類疾病”作為主要研究對象。大設(shè)施將重點建設(shè)轉(zhuǎn)化醫(yī)學核心設(shè)施、資源深度開發(fā)與共享設(shè)施和關(guān)鍵技術(shù)支撐設(shè)施三大板塊，與三大類疾病形成“三縱三橫”的建設(shè)格局。
重點建設(shè)標準化臨床生物樣本庫、臨床資源深度分析與挖掘平臺、生物標記物與藥物研發(fā)及新藥創(chuàng)制平臺、診斷試劑與儀器開發(fā)平臺、分子病理與影像技術(shù)研究平臺和臨床研究型病房六大平臺，通過搭建系統(tǒng)化、規(guī)模化、集成化的科學設(shè)施，開展從臨床實踐到基礎(chǔ)研究、醫(yī)藥產(chǎn)品和技術(shù)開發(fā)再回到臨床實踐的循環(huán)往復(fù)的轉(zhuǎn)化醫(yī)學研究。
新建成的瑞金醫(yī)院轉(zhuǎn)化醫(yī)學大樓擁有300張研究型病床（含50張萬級層流病床），按照國際一流標準進行設(shè)計和配置，是轉(zhuǎn)化醫(yī)學核心設(shè)施，用于開展大規(guī)模、前瞻性、規(guī)范化0-IV期臨床試驗，促進創(chuàng)新性療法、技術(shù)、診斷試劑在臨床的實踐。
目前大設(shè)施已初步建立起一支具有轉(zhuǎn)化醫(yī)學相關(guān)背景和工作經(jīng)驗、能勝任學科交叉融合的高層次專業(yè)技術(shù)人員隊伍。
National Center for Translational Medicine·Shanghai
——National Key Scientific Infrastructure for Translational Medicine
National Center for Translational Medicine·Shanghai (the Center for short hereinafter), which is a national key scientific infrastructure, was approved to be founded by National Development and Reform Commission in July 2013 and put into full operation in December 2020. As a national academic institution, the Center is co-administrated by Ministry of Education and Shanghai Municipal Government.
With an aim to promote the translation of frontier technologies and the findings of basic medical research into clinical practices, the Center has adopted a “systematic three by three” research scheme. Guided by the National Innovation Strategies and National Mid- and Long-Term Guidelines for Scientific Development, and to make the best of the advantages of Shanghai Jiao Tong University and Rui-Jin Hospital, the research of the Center is focused on three major types of life-threatening diseases: cancer, cardiovascular and cerebrovascular diseases, and metabolic diseases. To carry out the research, the Center prioritized building three main systems: translational research core facilities, a resource sharing system, and a key technical supporting system.
Through the building-up of 6 platforms, namely, biobank, in-depth clinical resources analysis platform, biomarker and new drug discovery platform, diagnostic reagents and new medical instrument development platform, pathological study and molecular imaging platform, the Center serves as a systematic and integrated platform for bed-bench-bed translational research.
The core facility of the Center, the newly inaugurated clinical research building of Rui-Jin Hospital, accommodates 300 research wards of international standard which are designed for large-scale, prospective and standard Phase 0-IV clinical trials to promote the application of new therapies, technologies and agents in clinical practices.
Presently, a high-level and multidisciplinary research team has been established in the Center.
